Posted by Michael Wonder on 24 Aug 2022
Avalglucosidase alfa for treating Pompe disease
24 August 2022 - NICE has published evidence-based recommendations on the use of avalglucosidase alfa for the treatment of patients with Pompe disease.
Avalglucosidase alfa is recommended, within its marketing authorisation, as an option for the treatment of babies, children, young people and adults with Pompe disease only if Sanofi provides avalglucosidase alfa according to the commercial arrangement.
